Molecular classification of estrogen receptor-positive/luminal breast cancers
FC Geyer, DN Rodrigues, B Weigelt… - Advances in Anatomic …, 2012 - journals.lww.com
Estrogen receptor (ER)-positive breast cancer is the most prevalent subtype of invasive
breast cancers. Patients with ER-positive breast cancers have variable clinical outcomes …
breast cancers. Patients with ER-positive breast cancers have variable clinical outcomes …
[HTML][HTML] The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2− invasive breast cancer
Abstract The Alliance for Clinical Trials in Oncology cooperative group has designed a
phase III neoadjuvant clinical trial (ALTERNATE trial) which randomizes women with cT2–4 …
phase III neoadjuvant clinical trial (ALTERNATE trial) which randomizes women with cT2–4 …
Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer data base …
Abstract Background The American College of Surgeons Oncology Group Z1031 trial
demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving …
demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving …
Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?
S Guiu, A Wolfer, W Jacot, P Fumoleau… - Critical reviews in …, 2014 - Elsevier
The WHO classification of breast tumors distinguishes, besides invasive breast cancer 'of no
special type'(former invasive ductal carcinoma, representing 60–70% of all breast cancers) …
special type'(former invasive ductal carcinoma, representing 60–70% of all breast cancers) …
PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer
AM Ohara, Y Naoi, K Shimazu, N Kagara… - Breast cancer research …, 2019 - Springer
Purpose There is an urgent need for the development of a predictor of response to
chemotherapy for ER-positive breast cancer which is less chemosensitive than for ER …
chemotherapy for ER-positive breast cancer which is less chemosensitive than for ER …
Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence
G Moon, H Noh, IJ Cho, J Lee, A Han - Breast Cancer, 2020 - Springer
Background Late recurrence accounts for nearly half of the recurrences in estrogen receptor
(ER)-positive breast cancer and decreases post-recurrence survival in patients with ER …
(ER)-positive breast cancer and decreases post-recurrence survival in patients with ER …
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison …
M Madeira, A Mattar, ÂF Logullo, FA Soares… - BMC cancer, 2013 - Springer
Background The role of estrogen receptor beta (ER-β) in breast cancer (BC) remains
unclear. Some studies have suggested that ER-β may oppose the actions of estrogen …
unclear. Some studies have suggested that ER-β may oppose the actions of estrogen …
How we treat HR-positive, HER2-negative early breast cancer
S Lopez-Tarruella, I Echavarria, Y Jerez… - Future …, 2022 - Taylor & Francis
The present goal of therapy for early HR+/HER2-breast cancer (BC) is to optimize disease-
free survival (DFS) and overall survival (OS) rates with the currently available therapies …
free survival (DFS) and overall survival (OS) rates with the currently available therapies …
Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
Y Delpech, C Coutant, L Hsu, E Barranger… - British journal of …, 2013 - nature.com
Background: The aim of this study was to compare clinical and pathological outcomes after
neoadjuvant chemotherapy between oestrogen receptor (ER)-positive invasive pure lobular …
neoadjuvant chemotherapy between oestrogen receptor (ER)-positive invasive pure lobular …
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial
Abstract Treatment of diabetics with metformin is associated with decreased breast cancer
risk in observational studies, but it remains unclear if this drug has clinical antineoplastic …
risk in observational studies, but it remains unclear if this drug has clinical antineoplastic …